Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Deferred Taxes (2016 - 2020)

Enanta Pharmaceuticals' Deferred Taxes history spans 7 years, with the latest figure at $15.0 million for Q3 2020.

  • For Q3 2020, Deferred Taxes rose 1363.63% year-over-year to $15.0 million; the TTM value through Sep 2020 reached $10.6 million, up 438.05%, while the annual FY2021 figure was $345000.0, 96.75% down from the prior year.
  • Deferred Taxes reached $15.0 million in Q3 2020 per ENTA's latest filing, up from -$3.1 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $15.0 million in Q3 2020 to a low of -$3.8 million in Q2 2017.
  • Average Deferred Taxes over 5 years is $263052.6, with a median of -$918000.0 recorded in 2018.
  • Peak YoY movement for Deferred Taxes: crashed 5816.67% in 2016, then skyrocketed 1363.63% in 2020.
  • A 5-year view of Deferred Taxes shows it stood at -$1.9 million in 2016, then skyrocketed by 239.37% to $2.7 million in 2017, then crashed by 134.49% to -$918000.0 in 2018, then skyrocketed by 171.57% to $657000.0 in 2019, then surged by 2179.15% to $15.0 million in 2020.
  • Per Business Quant, the three most recent readings for ENTA's Deferred Taxes are $15.0 million (Q3 2020), -$3.1 million (Q2 2020), and -$1.9 million (Q1 2020).